XML 30 R22.htm IDEA: XBRL DOCUMENT v3.24.3
Stock-based Compensation
9 Months Ended
Sep. 30, 2024
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]  
Stock-based Compensation

13. Stock-based Compensation

 

Under the Company’s 2015 New Employee Incentive Plan, as amended (the “2015 Plan”), awards may only be granted to employees who were not previously an employee or director of the Company, or following a bona fide period of non-employment, as a material inducement to entering into employment with the Company. On June 6, 2024, the Company’s Board increased the number of shares for future issuances under the 2015 Plan by 75,000 shares of common stock. As of September 30, 2024, there were 62,908 shares of common stock remaining and available for future issuances under the 2015 Plan.

 

The Company’s 2020 Stock Incentive Plan, as amended and restated (the “2020 Plan”), which replaced the Company’s 2014 Equity Incentive Plan, provides for the award or sale of shares of common stock (including restricted stock), the award of stock units and stock appreciation rights, and the grant of both incentive stock options to purchase common stock to directors, officers, employees and consultants of the Company. The 2020 Plan provides for the issuance of up to 1,236,667 shares of common stock, including an increase of 1,000,000 shares as approved by the Company’s stockholders at the Company’s 2024 annual stockholders’ meeting during the three months ended September 30, 2024, plus the number of shares of common stock available for issuance is increased to the extent that awards granted under the 2020 Plan and the Company’s 2014 Equity Incentive Plan are forfeited or expire (except as otherwise provided in the 2020 Plan). As of September 30, 2024, there were 692,596 shares remaining and available for future issuances under the 2020 Plan.

 

Generally, options issued under the 2020 Plan are subject to a two-year or four-year vesting schedule with 25% of the options vesting on the one year anniversary of the grant date followed by equal monthly installment vesting, and have a contractual term of 10 years.

 

A summary of activity for the nine months ended September 30, 2024 is as follows:

 

 

 

Options

 

 

Weighted
Average
 Exercise Price

 

 

Weighted
Average
Remaining
Contractual
Term (years)

 

 

Aggregate
Intrinsic Value

 

Balance as of December 31, 2023

 

 

140,109

 

 

$

37.48

 

 

 

8.07

 

 

 

 

Granted

 

 

506,127

 

 

$

1.58

 

 

 

 

 

 

 

Cancelled/expired

 

 

(47,696

)

 

$

38.02

 

 

 

 

 

 

 

Balance as of September 30, 2024

 

 

598,540

 

 

$

7.08

 

 

 

9.25

 

 

$

64,000

 

Vested and expected to vest at September 30, 2024

 

 

540,286

 

 

$

7.60

 

 

 

7.37

 

 

$

 

Exercisable at September 30, 2024

 

 

110,674

 

 

$

28.73

 

 

 

9.20

 

 

$

56,000

 

 

As of September 30, 2024, the total compensation cost related to non-vested stock options not yet recognized for all the Company’s plans is approximately $0.8 million, which is expected to be recognized as a result of vesting under service conditions over a weighted average period of 2.8 years.